

Appendix 1. Supplementary tables

Table IA. Antihyperglycemic management patterns

| Criteria | N | Mean | SD |
|--------------------------------|----|---------|----------|
| Duration of metformin (months) | 46 | 49.5 0 | 36.830 |
| Metformin starting dose/day | 46 | 1005.43 | 374.496 |
| Metformin most recent dose/day | 46 | 1646.74 | 2082.717 |
| Oral hypoglycaemic drugs | 28 | 1.32 | 0.548 |
| Non-oral hypoglycaemic drug | 27 | 1.33 | 0.55 |

Table IIA. HbA_{1c} % before and after each treatment group

| All hypoglycaemic drugs | N | Percentage % | Mean HbA _{1c} % (initial) | Mean HbA _{1c} % (most recent) |
|--|----|--------------|------------------------------------|--|
| Insulin only | 3 | 6.1 | 9.25 | 5.65 |
| Metformin only | 9 | 18.4 | 6.80 | 7.32 |
| Insulin and metformin | 10 | 20.4 | 9.74 | 9.91 |
| Insulin, metformin and oral hypoglycaemic drug | 16 | 32.7 | 10.50 | 9.53 |
| Metformin and oral hypoglycaemic drug | 11 | 22.4 | 10.50 | 9.70 |
| Non-oral hypoglycaemic drug | 27 | 1.33 | 1.33 | 0.55 |

Table IIIA. Oral hypoglycaemic drugs

| Oral hypoglycaemic drug | N | Percentage [%] |
|--|----|----------------|
| Total number of patients who take oral hypoglycaemic drugs | 28 | 57.1 |
| Sulfonylurea | 4 | 8.2 |
| TZD | 2 | 4.1 |
| DPP-4 inhibitor | 8 | 16.3 |
| GLP1_agonist | 6 | 12.2 |
| Sulfonylurea and TZD | 1 | 2.0 |
| Sulfonylurea and DPP-4 inhibitor | 5 | 10.2 |
| DPP-4 inhibitor and GLP1 agonist | 1 | 2.0 |
| Sulfonylurea, DPP-4 inhibitor, and GLP1 agonist | 1 | 2.0 |

Table IVA. Non-oral hypoglycaemic drugs

| Non-oral hypoglycaemic drug | N | Percentage [%] |
|---|----|----------------|
| Total number of patients who take non-oral hypoglycaemic drug | 27 | 55.1 |
| Total number of patients who take calciferol | 23 | 46.9 |
| Calciferol | 16 | 32.7 |
| Levothyroxine | 2 | 4.1 |
| Calciferol and levothyroxine | 3 | 6.1 |
| Calciferol and atorvastatin | 1 | 2.0 |
| Calciferol and amlodipine | 1 | 2.0 |
| Calciferol, liraglutide, and atorvastatin | 1 | 2.0 |
| Levothyroxine and lisinopril | 1 | 2.0 |
| Calciferol, levothyroxine, carvedilol, and perindopril | 1 | 2.0 |
| Atorvastatin | 1 | 2.0 |